A 50‑year‑old man presented at a tertiary hospital in Kathmandu, Nepal, with a palpable abdominal mass. Computed tomography (CT) measured the lesion at approximately 22.4 × 15.3 cm (≈9 inches), a size that raised concern for malignancy.
Fluid analysis proved decisive. After percutaneous drainage of the cyst, microscopic examination revealed microfilariae, the larvae of filarial worms. The final diagnosis was lymphatic filariasis, a mosquito‑borne parasitic infection most commonly associated with elephantiasis.
The case was reported by S. Kafle and B. Panthi in *ASM Case Reports* on September 8, 2025. Their analysis highlighted that lymphatic filariasis can remain asymptomatic for decades before manifesting as a sizable abdominal lesion.
A Mass Twice the Size Ultrasound Suggested
Initial ultrasound identified an 11.9 × 6. 6‑cm multiloculated cystic lesion. Subsequent CT demonstrated a substantially larger (22.44 × 15.29 cm), well‑defined but irregular mass located in the mesentery—the peritoneal fold that secures the intestines to the abdominal wall.
The lesion was causing intestinal obstruction. Given its cystic nature and the blockage, clinicians inserted a pigtail catheter for drainage and sent samples for oncologic, chemical, and microbiological analysis.
During the drainage, the patient developed acute hemorrhagic shock, prompting transfer to the intensive care unit. He was managed with intravenous fluids, blood transfusion, analgesics, and empiric antibiotics for suspected peritonitis.
Routine chemical and microbiological tests initially returned normal, but microscopic examination of the aspirated fluid uncovered numerous microfilariae.
Treated With Pills After the Fluid Gave It Away
Treatment comprised a single 400 mg dose of albendazole plus diethylcarbamazine 300 mg daily for 12 days. The patient’s clinical status improved markedly after initiating diethylcarbamazine therapy.
The case underscores the therapeutic implications: large mesenteric cysts often require surgical intervention, and a presumed malignancy could lead to radical procedures. Here, fluid analysis redirected both diagnosis and management.
The species of filarial worm was not specified. Approximately 90 % of global lymphatic filariasis cases are attributable to *Wuchereria bancrofti*, with *Brugia malayi* and *Brugia timori* accounting for the remainder. Adult parasites reside in the lymphatic vasculature and continuously release microfilariae into peripheral blood.
Abdominal cystic presentations due to filariasis are rare; a 2011 Indian series documented retro‑peritoneal cystic filariasis, emphasizing the rarity of this manifestation.
A Silent Infection in Millions
The majority of infected individuals are asymptomatic; the Centers for Disease Control and Prevention (CDC) estimates that most carriers never develop noticeable signs.
The global burden remains extensive. WHO reported that, as of 2023, 657 million persons across 39 countries required preventive anti‑helminthic therapy, with at least 36 million experiencing chronic sequelae such as limb edema and hydrocele. Infection typically occurs in childhood; even subclinical disease can cause progressive lymphatic and renal damage.
Transmission is mediated by multiple mosquito vectors—*Culex*, *Anopheles*, and *Aedes* spp. Adult worms have a lifespan of roughly six to eight years. Disruption of lymphatic drainage by the parasites leads to accumulation of interstitial fluid.
Thus, the Nepalese presentation likely reflected long‑standing, subclinical lymphatic injury that only became clinically apparent after a structural complication arose.
Nepal’s Long Campaign to Stop Transmission
Nepal has pursued an over‑two‑decade effort against lymphatic filariasis. Nationwide mass drug administration (MDA) began in 2003, targeting at‑risk communities with annual antiparasitic therapy. The country’s initial elimination target was 2020.
Coverage gaps limited success in certain regions. In 2022, the Ministry of Health introduced ivermectin into the standard regimen (diethylcarbamazine + albendazole) for high‑burden districts, a move reported by *The Kathmandu Post*. Officials have noted that lymphatic filariasis remains the nation’s second most common infectious cause of permanent disability after leprosy.
The target has been extended to 2030. By January 2026, WHO Nepal indicated that 57 of the 64 endemic districts had concluded MDA, with new rounds initiated that same month in Banke, Rautahat, Sarlahi, and Jhapa.
Interrupting transmission does not eliminate existing infections, and this case illustrates how dormant parasites can later manifest in atypical presentations. The report is a single observation and does not quantify the duration of infection. The authors conclude that clinicians in endemic regions should prioritize parasitic etiologies when encountering large cystic abdominal masses, rather than defaulting to malignancy.
Key Questions Answered
What happened to the man? A 50‑year‑old Nepali man presented with a large (≈22.4 × 15.3 cm), mesenteric cystic mass that obstructed his bowel.
Why was cancer suspected? The CT scan showed a large, irregular, well‑defined mass in the mesentery, a pattern typical of malignancy.
How was filariasis diagnosed? Microfilariae were identified microscopically in the fluid aspirated from the cyst.
How was he treated? He received a single 400 mg dose of albendazole plus 12 days of diethylcarbamazine (300 mg daily), resulting in marked clinical improvement.
How do people get lymphatic filariasis? Through bites from mosquitoes carrying filarial parasites, usually acquired in childhood, and often asymptomatic for many years.
Also Read
- NHS England Faces Scrutiny After 3,000 Patient Record Snooping Cases
- A Two-Week Nosebleed Defied Treatment Until Doctors Uncovered a Live Leech Inside a Man’s Nose
- Viz.ai Embeds UpToDate Expert AI Into Care Coordination Platform to Accelerate Clinical Decision-Making
- Acupuncture Thread Method Linked to Modest, Sustained Weight Loss in Chinese Trial

